https://orcid.org/0000-0002-5502-2595Our research focuses on developing innovative cancer therapeutics and molecular tools by engineering antibodies to improve treatment outcomes and advance biomedical research. We use synthetic design and directed evolution to generate highly potent and selective antibodies, which are engineered into diverse formats for anti-cancer applications, including bispecific antibodies, antibody-drug conjugates (ADCs), and multivalent antibody constructs. We are also developing a versatile platform based on our discovery of unconventional antigen-binding mode, enabling the efficient generation of renewable, high-performance antibody reagents against challenging targets such as post-translational modifications.